ATE290385T1 - Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten - Google Patents
Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthaltenInfo
- Publication number
- ATE290385T1 ATE290385T1 AT00912877T AT00912877T ATE290385T1 AT E290385 T1 ATE290385 T1 AT E290385T1 AT 00912877 T AT00912877 T AT 00912877T AT 00912877 T AT00912877 T AT 00912877T AT E290385 T1 ATE290385 T1 AT E290385T1
- Authority
- AT
- Austria
- Prior art keywords
- cgs
- nerve
- analogs
- resulting
- activities
- Prior art date
Links
- 230000001737 promoting effect Effects 0.000 title abstract 2
- 230000024245 cell differentiation Effects 0.000 title 1
- 150000002315 glycerophosphates Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 210000002569 neuron Anatomy 0.000 title 1
- 210000005036 nerve Anatomy 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- -1 Cyclic glycerophosphates Chemical class 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010056677 Nerve degeneration Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12917899A IL129178A0 (en) | 1999-03-25 | 1999-03-25 | Induction of nerve generation |
| PCT/IL2000/000185 WO2000057865A2 (en) | 1999-03-25 | 2000-03-24 | Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE290385T1 true ATE290385T1 (de) | 2005-03-15 |
Family
ID=11072645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00912877T ATE290385T1 (de) | 1999-03-25 | 2000-03-24 | Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6914056B1 (enExample) |
| EP (1) | EP1162959B1 (enExample) |
| JP (1) | JP2002540146A (enExample) |
| KR (1) | KR20010112364A (enExample) |
| CN (1) | CN1348375A (enExample) |
| AT (1) | ATE290385T1 (enExample) |
| AU (1) | AU768911B2 (enExample) |
| BR (1) | BR0009296A (enExample) |
| CA (1) | CA2368597A1 (enExample) |
| DE (1) | DE60018554T2 (enExample) |
| HK (1) | HK1042038A1 (enExample) |
| IL (1) | IL129178A0 (enExample) |
| MX (1) | MXPA01009650A (enExample) |
| NZ (1) | NZ514525A (enExample) |
| RU (1) | RU2247557C2 (enExample) |
| WO (1) | WO2000057865A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE253918T1 (de) | 1999-12-08 | 2003-11-15 | Centre Nat Rech Scient | Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel |
| JP4815063B2 (ja) * | 2001-04-13 | 2011-11-16 | きみ子 室伏 | 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び／又は生存の促進のための薬剤 |
| JP4836345B2 (ja) * | 2001-04-13 | 2011-12-14 | きみ子 室伏 | 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤 |
| IL148665A0 (en) * | 2002-03-13 | 2002-09-12 | Yeda Res & Dev | Derivatives of 1,3-cyclic propandiol phate and their action as cell stimulants |
| IL148668A0 (en) * | 2002-03-13 | 2002-09-12 | Yeda Res & Dev | Derivatives of 1,3-cyclic propandiol phosphate and their action in differentiation therapy |
| EP1511483A4 (en) * | 2002-03-27 | 2009-03-18 | Smithkline Beecham Corp | PROCESSING METHODS USING LXR MODULATORS |
| JP4162927B2 (ja) | 2002-06-11 | 2008-10-08 | きみ子 室伏 | カルバ環状ホスファチジン酸誘導体 |
| US8101552B2 (en) * | 2005-03-14 | 2012-01-24 | Yeda Research And Development Company Ltd. | Cyclic phosphates as plant growth regulators |
| NZ571975A (en) * | 2006-04-26 | 2011-04-29 | Toyama Chemical Co Ltd | Neurogenesis inducer or neuropathy therapeutic agent comprising benzothiopene alkyl ether derivative or salt thereof |
| EP2098237B1 (en) * | 2006-12-28 | 2012-08-29 | Ochanomizu University | Analgesic agent comprising cyclic phosphatidic acid derivative |
| WO2010080969A1 (en) * | 2009-01-09 | 2010-07-15 | Sigma-Aldrich Co. | Process for the synthesis of beta glycerol phosphate |
| WO2011065480A1 (ja) * | 2009-11-26 | 2011-06-03 | 国立大学法人お茶の水女子大学 | 神経細胞死抑制剤 |
| JP6007264B2 (ja) | 2013-01-28 | 2016-10-12 | 国立大学法人お茶の水女子大学 | 脱髄疾患治療薬 |
| EP2807925A1 (en) * | 2013-05-26 | 2014-12-03 | Symrise AG | Antimicrobial compositions |
| CA3007063A1 (en) * | 2015-12-08 | 2017-06-15 | Retrophin, Inc. | Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL63037A (en) * | 1981-06-04 | 1985-12-31 | Israel State | Dioxaphosphorinanes,their preparation and pharmaceutical and veterinary compositions containing them |
| US5565439A (en) * | 1992-11-24 | 1996-10-15 | The Procter & Gamble Company | Methods of using lysophosphatidic acid for treating hyperproliferative conditions |
| JPH06228169A (ja) * | 1993-02-05 | 1994-08-16 | Sagami Chem Res Center | １−ｏ−アシルグリセロール２，３−ホスフェートの製造法 |
| JPH07149772A (ja) * | 1993-11-26 | 1995-06-13 | Sagami Chem Res Center | タンパク質リン酸化酵素ｃの活性促進剤 |
| JPH07258278A (ja) * | 1994-03-18 | 1995-10-09 | Sagami Chem Res Center | １−Ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするＤＮＡポリメラーゼαの阻害剤 |
| JPH0925235A (ja) * | 1995-07-13 | 1997-01-28 | Sagami Chem Res Center | １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤 |
| US6150345A (en) * | 1998-08-10 | 2000-11-21 | Regents Of The University Of California | Methods for promoting survival of myelin producing cells |
| IL129179A0 (en) * | 1999-03-25 | 2000-02-17 | Yeda Res & Dev | Cyclic glycerophosphates and analogs thereof |
-
1999
- 1999-03-25 IL IL12917899A patent/IL129178A0/xx unknown
-
2000
- 2000-03-24 CN CN00806738A patent/CN1348375A/zh active Pending
- 2000-03-24 EP EP00912877A patent/EP1162959B1/en not_active Expired - Lifetime
- 2000-03-24 JP JP2000607616A patent/JP2002540146A/ja active Pending
- 2000-03-24 NZ NZ514525A patent/NZ514525A/en unknown
- 2000-03-24 CA CA002368597A patent/CA2368597A1/en not_active Abandoned
- 2000-03-24 DE DE60018554T patent/DE60018554T2/de not_active Expired - Fee Related
- 2000-03-24 RU RU2001128743/15A patent/RU2247557C2/ru not_active IP Right Cessation
- 2000-03-24 AT AT00912877T patent/ATE290385T1/de not_active IP Right Cessation
- 2000-03-24 AU AU34517/00A patent/AU768911B2/en not_active Ceased
- 2000-03-24 MX MXPA01009650A patent/MXPA01009650A/es not_active Application Discontinuation
- 2000-03-24 KR KR1020017012158A patent/KR20010112364A/ko not_active Withdrawn
- 2000-03-24 US US09/936,922 patent/US6914056B1/en not_active Expired - Fee Related
- 2000-03-24 WO PCT/IL2000/000185 patent/WO2000057865A2/en not_active Ceased
- 2000-03-24 BR BR0009296-7A patent/BR0009296A/pt not_active IP Right Cessation
- 2000-03-24 HK HK02101620.4A patent/HK1042038A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1162959B1 (en) | 2005-03-09 |
| CN1348375A (zh) | 2002-05-08 |
| US6914056B1 (en) | 2005-07-05 |
| IL129178A0 (en) | 2000-02-17 |
| DE60018554T2 (de) | 2006-04-13 |
| WO2000057865A3 (en) | 2001-06-28 |
| RU2247557C2 (ru) | 2005-03-10 |
| AU768911B2 (en) | 2004-01-08 |
| JP2002540146A (ja) | 2002-11-26 |
| NZ514525A (en) | 2003-10-31 |
| MXPA01009650A (es) | 2002-07-02 |
| BR0009296A (pt) | 2001-12-18 |
| WO2000057865A9 (en) | 2001-11-15 |
| EP1162959A2 (en) | 2001-12-19 |
| KR20010112364A (ko) | 2001-12-20 |
| AU3451700A (en) | 2000-10-16 |
| HK1042038A1 (zh) | 2002-08-02 |
| WO2000057865A2 (en) | 2000-10-05 |
| DE60018554D1 (de) | 2005-04-14 |
| CA2368597A1 (en) | 2000-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE290385T1 (de) | Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten | |
| Kaye et al. | Modest facilitation of memory in dementia with combined lecithin and anticholinesterase treatment. | |
| EP0348353A3 (en) | The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases | |
| AU637086B2 (en) | Use of 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in the preparation of pharmaceutical compositions in controlled- release form active in the therapy of organic mental disturbances, and the relative pharmaceutical compositions | |
| EP0616032A3 (en) | Preventive or therapeutic agents against Alzheimer's disease, a screening method and the human tau kinase protein. | |
| DE236684T1 (de) | Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit. | |
| DE69333775D1 (de) | Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten | |
| ATE271874T1 (de) | Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen | |
| IL104006A (en) | Azaheterocyclylmethyl-chromans their preparation and pharmaceutical compositions containing them | |
| PL342078A1 (en) | Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas | |
| PL398445A1 (pl) | Kompozycje farmaceutyczne zawierające dekstrometorfan i chininę do leczenia zaburzeń neurologicznych | |
| SI0725779T1 (enExample) | ||
| EP0858996A4 (en) | AGENT FOR PROTECTING NERVOUS CELLS | |
| ATE213411T1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| ATE444077T1 (de) | Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen | |
| EP0103290A3 (de) | Pharmazeutische Zubereitungen zur Behandlung von unerwünschten Verwachsungen sowie deren Verwendung | |
| DE69636934D1 (de) | Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen | |
| EP0267676A3 (en) | Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases | |
| Gustafson et al. | Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia | |
| ATE167060T1 (de) | Epidermis-wachstumsfaktor als arzneimittel zur wiederherstellung der neuronen der substantia nigra in der behandlung nervenzerstörender störungen | |
| IL109076A0 (en) | Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them | |
| ATE143809T1 (de) | Placentaextrakt und verfahren zu seiner herstellung | |
| DE60039579D1 (de) | Humane adulte astrozyten, sowie deren herstellung und verwendung | |
| EP0495998A4 (enExample) | ||
| DE68901172D1 (de) | (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |